Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use
Frontiers in Plant Science · 27.02.2023 · 14
DOI: 10.3389/fpls.2023.1126470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Plant Science, online erschienen am 27.02.2023. Verfasst von Melanie Grandits und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunology Unit, Institute for Infection and Immunity, St. George's University of London, London, United Kingdom. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Introduction
Broadly neutralising antibodies are promising candidates for preventing and treating Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), as an alternative to or in combination with antiretroviral therapy (ART). These mAbs bind to sites on the virus essential for virus attachment and entry, thereby inhibiting entry into the host cell. However, the cost and availability of monoclonal antibodies, especially combinations of antibodies, hampers implementation of anti-HIV bNAb therapies in low- to middle- income countries (LMICs) where HIV-1 prevalence is highest.
Methods
We have produced three HIV broadly neutralizing antibodies (bNAbs), 10-1074, VRC01 and 3BNC117 in the Nicotiana benthamiana transient expression system. The impact of specific modifications to enhance potency and efficacy were assessed. To prolong half-life and increase bioavailability, a M252Y/S254T/T256E (YTE) or M428L/N434S (LS) mutation was introduced. To increase antibody dependent cellular cytotoxicity (ADCC), we expressed an afucosylated version of each antibody using a glycoengineered plant line.
Results
The majority of bNAbs and their variants could be expressed at yields of up to 47 mg/kg. Neither the expression system nor the modifications impacted the neutralization potential of the bNAbs. Afucosylated bNAbs exhibit enhanced ability to bind to FcγRIIIa and trigger ADCC, regardless of the presence of Fc amino acid mutations. Lastly, we demonstrated that Fc-modified variants expressed in plants show enhanced binding to FcRn, which results in a favourable in vivo pharmacokinetic profile compared to their unmodified counterparts.
Conclusion
Tobacco plants are suitable expression hosts for anti-HIV bNAbs with increased efficacy and an improved pharmacokinetic profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Immunology Unit, Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
- Core Facility Mass Spectrometry, University of Natural Resources and Life Sciences, Vienna, Austria.
- Infection, Immunity and Inflammation Research and Teaching Department, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom.
Förderung
- Medical Research Council
Zitieren
APA
Grandits, M., Grünwald-Gruber, C., Gastine, S., Standing, J. F., Reljic, R., Teh, A. Y., & Ma, J. K. (2023). Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use. Frontiers in Plant Science, 14. https://doi.org/10.3389/fpls.2023.1126470
Vancouver
Grandits M, Grünwald-Gruber C, Gastine S, Standing JF, Reljic R, Teh AY, et al. Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use. Frontiers in Plant Science. 2023;14. doi:10.3389/fpls.2023.1126470
BibTeX
@article{Grandits2023,
author = {Grandits, Melanie and Grünwald-Gruber, Clemens and Gastine, Silke and Standing, Joseph F and Reljic, Rajko and Teh, Audrey Y-H and Ma, Julian K-C},
title = {Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use},
journal = {Frontiers in Plant Science},
year = {2023},
volume = {14},
doi = {10.3389/fpls.2023.1126470}
}
EUVIMED